| |
EPA/DHA 1:1
|
EPA/DHA 2:1
|
EPA/DHA 1:2
|
Soybean oil
|
Linseed oil
|
|---|
|
Biomarkers
|
Mean ± SD
|
Mean ± SD
|
Mean ± SD
|
p
|
Mean ± SD
|
P
|
Mean ± SD
|
p
|
|---|
|
CV RISK FACTORS
|
|---|
|
Lipid profile
|
|
TG (mg/dL)
|
86.3 ± 65.1
|
124.5 ± 102.2
|
83.1 ± 10.4
| |
108.5 ± 51.9
| |
73.5 ± 25.2
| |
|
CHOL (mg/dL)
|
93.3 ± 26.5
|
98.0 ± 14.8
|
112.3 ± 20.8
| |
125.8 ± 16.5
| |
118.5 ± 13.5
| |
|
LDLc (mg/dL)
|
7.64 ± 3.3
|
7.4 ± 0.8
|
8.30 ± 1.3
| |
10.39 ± 2.2
| |
7.4 ± 1.6
| |
|
HDLc (mg/dL)
|
37.4 ± 11.1
|
50.4 ± 25.9
|
47.3 ± 8.1
| |
51.3 ± 7.8
| |
46.8 ± 5.5
| |
|
LDLc/HDLc
|
0.19 ± 0.5
|
0.20 ± 0.01
|
0.17 ± 0.01
| |
0.20 ± 0.2
| |
0.19 ± 0.1
| |
|
ApoA1 (mg/mL)
|
43.0 ± 11.4
|
51.7 ± 11.9
|
47.9 ± 13.8
| |
51.4 ± 13.3
| |
30.6 ± 2.1
| |
|
ApoB100 (mg/mL)
|
116.5 ± 16.8
|
137.0 ± 6.4
|
139.4 ± 23.8
| |
126.8 ± 13.9
| |
152.7 ± 35.7
| |
|
ApoB100/ApoA1
|
2.79 ± 0.51
|
2.75 ± 0.54
|
3.10 ± 1.01
| |
2.67 ± 1.11
| |
5.02 ± 1.29
|
a0.029
|
| | | | | | | |
b0.019
|
| | | | | | | |
d0.029
|
|
Glycaemia
|
|
Glucose increase (mmol/L)
|
-0.75 ± 0.42
|
-0.15 ± 0.34
|
0.27 ± 0.49
|
a0.001
|
0.53 ± 0.25
|
a < 0.001
|
- 0.20 ± 0.31
|
d0.032
|
|
Glycated Haemoglobin (%)
|
4.14 ± 0.24
|
4.43 ± 0.72
|
4.17 ± 0.30
| |
6.39 ± 0.99
|
a0.003
|
6.34 ± 1.84
|
a0.025
|
| | | | | |
b0.007
| |
b0.05
|
| | | | | |
c0.004
| |
c0.032
|
|
Insulin increase (ng/mL)
|
1.40 ± 0.8
|
0.15 ± 1.90
|
0.42 ± 0.4
| |
0.9 ± 1.5
| |
0.41 ± 0.5
| |
|
Homa index
|
7.0 ± 3.0
|
4.1 ± 1.8
|
3.8 ± 1.5
| |
6.9 ± 3.8
| |
2.9 ± 1.1
|
a0.004
|
| | | | | | | |
d0.032
|
- The data are expressed as mean ± SD (standard deviation). a: differences with respect to EPA/DHA 1:1 supplementation; b: differences with respect to EPA/DHA 2:1 supplementation; c: differences with respect to EPA/DHA 1:2 supplementation; d: differences with respect to soybean oil supplementation.
